A Phase I/II Trial of VELCADE & Gemcitabine for Patients With Relapsed or Refractory Aggressive B- and T-cell Non-Hodgkin's Lymphoma
Stopped early · Phase 1/Phase 2
Conditions studied: Lymphoma
In brief
RATIONALE: Drugs used in chemotherapy, such as gemcitabine, work in different ways to stop the growth of cancer cells, either by killing the cells or by stopping them from dividing. Bortezomib may stop the growth of cancer cells by blocking some of the enzymes needed for cell growth. Giving gemcitabine together with bortezomib may kill more cancer cells. PURPOSE: This phase I/II trial is studying the side effects and best dose of bortezomib when given together with gemcitabine and to see how well they work in treating patients with relapsed or refractory B-cell or T-cell non-Hodgkin's lymphoma.
Key facts
- Study ID
- NCT00290706
- Run by
- Northwestern University
- People needed
- 32
- Starts
- 2006-04-07
- Expected to finish
- 2012-09-05
- Last updated by the study team
- 2019-05-28
Who can join
Age: 18 and older. Sex: any. Healthy volunteers: not accepted.
Where it is running
- Northwestern University — Chicago, Illinois, United States
- Veterans Affairs Medical Center - Lakeside Chicago — Chicago, Illinois, United States
- University of Chicago Cancer Research Center — Chicago, Illinois, United States
Full record on ClinicalTrials.gov
Trial information comes from ClinicalTrials.gov and is refreshed daily. TrialsForMe does not provide medical care and does not run the studies it lists.